Drug reference

Daclizumab

Monoclonal Antibody · Immunosuppressant

Also known as ZENAPAX

Monoclonal AntibodyImmunosuppressant

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Daclizumab is a humanized monoclonal antibody that binds to the CD25 subunit of the interleukin-2 receptor (IL-2R) on the surface of activated, but not resting, T cells. This binding blocks IL-2-mediated T-cell activation, targeting growth-factor pathways. The mechanism limits clonal expansion of T cells and potentially promotes immune tolerance, resulting in a relative decrease of the expression of the α chain of the IL-2 receptor.

Indications

Organ transplantationAutoimmune diseaseAcute immune rejection of organ transplantsPrevention of transplant rejectioninduction therapy in solid-organ transplantationms (second-line)prophylaxis of acute organ transplant rejection

Dosing

Adult: is a low dose of an ICS, although a leukotriene receptor antagonist may be used as an alternative. An important caveat for patients with mild asthma is that although the risk of a severe, lifethreatening attack is low, it is not zero.…